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Effects of estradiol (E2) on the urinary bladder of old female rats were investigated by
morphological, immunohistochemical and apoptosis-related gene analysis.  Sixteen-
month-old female Wistar rats were divided into the following 5 groups:  normal controls;
rats replaced with low-dose E2 for 2 and 4 weeks, respectively; and rats replaced with
high-dose E2 for 2 and 4 weeks, respectively.  After treatment, the bladders were remov-
ed, weighed and stained with hematoxylin and eosin, and immunostained by monoclonal
antibodies against Bcl-2 and Bax proteins.  Further, the expression of apoptosis-related
genes bcl-2 and bax were investigated by PCR analysis, and evaluated by computerized
quantification.  Immunostained bladders showed no difference between control and
E2-replaced rats in reactivity against Bcl-2 protein.  In contrast, against Bax protein,
control rats showed immunoreactivity, whereas E2-replaced rats showed little reactivity.
Upon mRNA analysis, the expression of bax mRNA was suppressed in the E2-replaced
rats as compared with the controls, though the expression of bcl-2 mRNA showed no
difference among groups.  These results suggest that E2 administration affects the ex-
pression of apoptosis-related genes and suppressees apoptotic action, and that these
changes could consequently alter voiding behavior.
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The decrease in serum level of estrogen that
occurs in menopause causes metabolic and
atrophic alterations in many organs.  Postmeno-
pausal urogenital atrophy causes pollakiuria,
urinary urgency, stress and urge incontinence,
dysuria and so on (Versi, 1990).  The symptoms
show increasing incidence with age (Eika et al.,
1990).
Previous investigations have demonstrated
the presence of estrogen receptors in the human
lower urinary tract.  This supports the practice
of giving estrogen treatment to postmenopausal
women with lower urinary tract dysfunction.
Estrogen has been found to improve lower uri-
nary tract function in postmenopausal women
(Batra et al., 1987; Iosif et al., 1981).
A decrease in serum estrogen results in an
increase of collagen in the bladder.  Large inter-
spaces between the muscle cells of the bladder
and smooth muscles with hypertrophy were ob-
served in old female rats.  The interspaces were
occupied by collagen fibrils.  The collagen con-
tent of the detrusor muscle, which could be af-
fected by estrogen concentration in the serum,
has been found to be significantly increased in
women after the age of 50 years as compared to
younger women and to men of the same age
(Eika et al., 1990).  Increased collagen deposits
between the smooth muscle cells of the detrusor
and the urethra might affect the functional prop-
erties of the lower urinary tract, and estrogen is
considered to influence the lower urinary tract.
On the other hand, several studies have
indicated that estrogen regulates cell survival
and death factors.  Estrogen administration
decreases apoptosis.  In breast cancer cells
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(Teixeria et al., 1995; Kandouz et al., 1996; Huang
et al., 1997) and brain cells (Dubal et al., 1999),
respectively, estrogen was shown to have an
effect on mRNA expression of bcl-2, bad and
bax, and, ultimately, to prevent the preapoptotic
actions of the members of the bcl-2 family such
as bax and bad.
In the present study which uses female rats
after menopause, the effects of estrogen re-
placement therapy on their bladders were inves-
tigated, including the effects on the expressions
of bcl-2 and bax.
Materials and Methods
Animals
All animal experiments were performed in
accordance with the guidelines set out by the
Tottori University Committee for Animal Ex-
perimentation.  Sixteen-month-old female
Wistar rats were divided into 5 groups.  In
group I, no hormonal treatment was carried out
(control group; n = 8).  In group II, a silastic
tube containing estradiol (E2) dissolved in
sesame oil at 10 µg was subcutaneously
placed for 2 weeks from the age of 16 months,
without an ovariectomy (low-dose E2 replaced
for 2 weeks; n = 8).  In group III, E2 was admin-
istered for 4 weeks in the same manner as in
group II (low-dose E2 replaced for 4 weeks; n =
8).  In group IV, E2 was replaced in the form of
silastic capsules containing 2.5 mg β-E2 for 2
weeks (high-dose E2 replaced for 2 weeks; n =
8), and in group V, the same capsules as in
group IV were given for 4 weeks (high-dose E2
replaced for 4 weeks; n = 8).  Rats in the control
group received placebos by the same methods
as E2-replaced rats.  All animals were kept in an
air-conditioned room lighted 12 h a day, and
allowed access to food and water ad libitum.
Measurement of plasma E2
Plasma E2 concentrations were measured when
the rats were 16 months old in the control
group, and in E2-replaced groups, 2 weeks
(groups II and V) or 4 weeks (groups III and V)
after hormone replacement.
Histological examination of the rat blad-
der and reverse transcription-PCR analy-
sis
Animals at the age of 16 months or after re-
placement therapy were all anesthetized by an
intraperitoneal injection of sodium pentobarbi-
tal and then weighed.  The bladder was remov-
ed and weighed after emptying the urine.  Four
bladders per group were placed in 10% forma-
lin and embedded in paraffin.  Each paraffin
block was serially sectioned and routinely
stained with hematoxylin and eosin (HE).  The
serial sections were also immunohistochemi-
cally stained by the monoclonal antibody
against Bcl-2 (Santa Cruz Biotechnology, Santa
Cruz, CA) or Bax (Santa Cruz Biotechnology)
in a buffer diluted 1:100 with phosphate-buffer-
ed saline.  Diaminobenzidine tetrahydrochlo-
ride was used as the final chromogen.
After weighing, 4 bladders per group were
frozen in liquid nitrogen.  Total RNA was ex-
tracted from the dissected tissues using TRIzol
reagent (Invitrogen Corporation, Carlsbad, CA)
according to the manufacturer’s instructions
and then quantified spectrophotometrically.
Reverse transcription (RT) was carried out with
Moloney murine leukemia virus reverse tran-
scriptase (Roche Molecular Systems, Branchburg,
NJ), and PCR was performed using AmpliTag
gold DNA polymerase (Roche Molecular Sys-
tems).  For bcl-2 and bax cDNA amplification,
the primers were 5'-CACCCCTGGCATCTT
CTCCTT-3' (sense) and 5'-AGCGTCTTCAGA
GACAGCCAG-3' (antisense) for bcl-2 (Genbank
accession number  U34964, 519-bp DNA frag-
ment), and 5'-CACCAGCTCTGAACAGAT
CATGA-3' (sense) and 5'-TCAGCCCATCTT
CTTCCAGATGGT-3' (antisense) for bax
(Genbank accession number RRU 49729, 540-
bp DNA fragment) according to the method of
Ananth et al. (2001).  The PCR cycles consisted
of denaturation at 94˚C for 30 s, annealing at
68˚C for 30 s and extension at 72˚C for 1 min
for 25 cycles (bcl-2); and denaturation at 94˚C
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for 30 s, annealing 62˚C for 30 s and extension
at 72˚C for 1 min for 25 cycles (bax).  As an
internal control, a 285-bp DNA fragment of rat
β-actin was also amplified using the following
primers: 5'-TCATGAAGTGTGACGTTG
ACATCCGT-3' (sense) and 5'-CCTAGAA
GCATTTGCGGTGCAGGATG-3' (antisense).
The temperature cycling conditions were as
follows: 10 min at 94˚C 18 cycles of (94˚C for
30 s, 65˚C for 30 s, 72˚C for 30 s) and a final
extension at 72˚C for 30 s.
In this experiment, 5 µg of total RNA was
reverse-transcribed in a 15-µL reaction volume.
An 8-µL aliquot of each PCR product was size-
separated by electrophoresis on a 2% cyber
green-containing agarose gel and photograph-
ed.  For quantification, photographs showing
PCR products were scanned and analyzed  us-
ing Densitograph version 4.0 software (ATTO
Corp., Tokyo, Japan).  For each sample, the
PCR product values were normalized to β-actin
PCR product values.  Data were analyzed by
Student’s t-test.
Results
Plasma E2 levels
Plasma E2 levels ranged from 15 to 45 pg/mL in
low-dose E2-replaced groups (groups II and
III), from 100 to 330 pg/mL in high-dose E2-
replaced groups (groups IV and V) and less than
10 pg/mL in the control group.
Serum E2 levels in the replaced groups were
significantly higher than those in the control
group.  Compared in terms of the E2 dose,
serum E2 levels were significantly higher in the
high-dose groups (groups IV and V) than in the
low-dose groups (groups II and III) (Table 1).
Body and bladder weight
There were no significant differences among
groups in body weight.  However, E2-replaced
groups showed a lower tendency in mean body
weight than the control group:  body weight
tended to be higher as the E2 dose was increas-
ed.
On the other hand, bladder weight was sig-
nificantly heavier in the E2-replaced groups
than in the control group, except for group II
replaced with low-dose E2 for 2 weeks.  The
mean bladder weight showed no significant
differences among the low- and high-dose
replaced groups (Table 1).
Histological changes in the rat bladders
There were no significant differences between
control and E2-replaced rats in the HE stains of
the bladder.
Table 1.  Body weight, bladder weight and serum E2 levels
Body weight Bladder weight Serum E2 levels
                      Group (g) (mg) (pg/mL)
   I: control 353.5 ± 37.0 110.7 ± 10.4     7.3 ±   2.5
 II: low-dose E2 replaced for 2 wk 358.7 ± 28.0 116.1 ± 10.6   25.0 ±   4.8
III: low-dose E2 replaced for 4 wk 339.0 ± 24.3 136.5 ± 24.8   29.4 ± 10.7
IV: high-dose E2 replaced for 2 wk 332.2 ± 34.4 124.2 ±   9.3 258.1 ± 55.0
 V: high-dose E2 replaced for 4 wk 340.0 ± 23.2 128.3 ± 10.5 213.6 ± 67.3
E2, estradiol; wk, weeks.
  * Significant difference; P < 0.05.
** Significant difference; P < 0.01.
**
*
**
**
*
**
**
*
**
*
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Figs. 1ab.  Immunohistochemical stains of rat bladders by an antibody against Bcl-2 protein.  a:  A control rat
(× 100).  b:  A group-V rat replaced with high-dose E2 for 4 weeks (× 100).
Figs. 2ab. Immunohistochemical stains of rat bladders by an antibody against Bax protein.  a:  A control rat
(× 100).  b:  A group-V rat replaced with high-dose E2 for 4 weeks (× 100).
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Figs. 3ab.
a:  Semiquantitative RT-PCR analysis of mRNA expression of bcl-2, bax and β-actin in rat bladders.  RT,
reverse transcription.
b:  Relative densities of bcl-2 and bax mRNA signals.  The signals are normalized with corresponding β-actin
signals.  Each bar represents the mean ± SEM.  Statistical significances were examined in comparison to
the control level expressed as 100%:  **Significant difference; P < 0.01.  Group I, control; group II,
replaced with low-dose E2 for 2 weeks; group III, replaced with low-dose E2 for 4 weeks; group IV,
replaced with high-dose E2 for 2 weeks; group V,  replaced with high-dose E2 for 4 weeks; E2, estratiol.
Figures 1a and b show representative light
microscopic photographs of the bladders immu-
nostained by the antibody against Bcl-2:  Fig.
1a for a control rat and Fig. 1b for a group-V rat
replaced with high-dose E2 for 4 weeks.  Both
stains of the bladders demonstrate low immuno-
reactivity against Bcl-2, not different in appear-
ance.
Figures 2a and b show bladders similarly
stained by the antibody against Bax in a control
rat and a group-V rat.  Bax was detected in the
mucosal region of the bladder of the control rat
(Fig. 2a), but not in the bladder of the E2-replaced
rat (Fig. 2b).
RT-PCR analysis of expression of bcl-2
and bax mRNA
The expressions of bcl-2 mRNA were not sig-
nificantly different among groups.  In contrast,
the expressions of bax mRNA were significant-
ly decreased in groups III to V as compared
with the control group.  In group II, the expres-
sion of bax mRNA was almost the same level as
that in the control group (Fig. 3).
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Discussion
In the present study, plasma E2 levels were
lower than 10 pg/mL in the control group.  It is
well known that rats have a fertility period that
lasts until the age of approximately 15 months,
at which time the estrous cycle ceases.  The
values of plasma E2 in the control group re-
flected this time frame, and the estrous cycle
disappeared in control rats.  In the E2-replaced
groups, the mean plasma E2 levels reached over
20 pg/mL in low-dose groups and 200 pg/mL in
high-dose groups.  In high-dose groups, the
plasma E2 level was quite over the peak level of
E2 throughout the usual estrous cycle (Handa et
al., 1987; Shulman et al., 1987; Albert et al.,
1991).   Albert et al. (1991) found that a plasma
E2 level of 15 pg/mL was slightly below the
mean level of E2 present throughout the estrous
cycle in rats maintaining normal body weight.
Therefore, the method of E2 replacement in this
experiment is adequate in studying the effect of
E2 on the rat bladder.
Previous studies demonstrated that ovariec-
tomized rats showed an increase in body weight
and a decrease in bladder weight as compared
with control rats (Lonhurst et al., 1992).  In the
present study, no significant difference in mean
body weight was observed among groups;
however, there was a linear correlation between
the E2 dose and rat body weight.  When the E2
dose was increased, body weight tended to be
higher.  Further, mean bladder weight was sig-
nificantly lower in control rats than E2-replaced
rats, except for those receiving low-dose E2 for
2 weeks (group II).  These results suggest that
E2 replacement after menopause increases blad-
der weight while decreasing body weight in
rats.  The explanation for these changes is not
clear, but it is suspected that the lack of E2
causes a reduction in physical activity and E2
replacement abolishes this reduction.
On the other hand, in E2-replaced rats, the
bladder might gain weight as the collagen con-
tent of the bladder increases and the bladder
epithelium thickens (Suguita et al., 2000; Eika
et al., 1990).  Suguita et al. (2000) performed E2
replacement in female rats:  they compared the
obtained results with the parameters in the
progesterone-replaced group, and found an in-
crease in thickness of the mucosa of the bladder
and the proximal urethra.  The present study,
however, showed no significant difference in
the HE stains of bladders between control and
E2-replaced rats.  It might have been difficult to
detect differences in the bladder mucosa or col-
lagen content by HE staining due to the fact that
the bladder weight increased 10% to 20%.
In the present histological study, immuno-
reactivity with the Bcl-2 antibody was weak in
the bladder of control and E2-replaced rats.
However, the immunoreactivity with the Bax
antibody was stronger in the control rats than in
E2-replaced rats.
RT-PCR analysis for bcl-2 showed no sig-
nificant difference among the groups.  Upon bax
analysis, however, the expression was stronger
in the control group than in the E2-replaced
groups, except for group II (low-dose E2 replaced
for 2 weeks).  Considering the histological re-
sults, it seems that E2 replacement suppresses
the bax gene expression in the mucosa of the rat
bladder.  In group II replaced with low-dose E2
for 2 weeks, the E2 dose might have been too
low or the administration period might have
been too short to cause a difference in gene ex-
pression.
It is clear from previous studies that the bcl-
2 gene prolongs cell survival without affecting
proliferation and that the bcl-2 gene is able to
prevent apoptosis induced by growth factor
deprivation.  The mechanism by which bcl-2
exerts its antiapoptotic effect is not fully clear,
although it has been speculated that bcl-2 acts
either as a regulator of an antioxidant pathway
that prevents oxidative damage such as lipid
peroxidation caused by the generation of free
radicals (Tsujimoto et al., 1986; Hockenbery et
al., 1993) or as a regulator of intracellular Ca2+
compartmentalization (Kane et al., 1993).  bcl-2
is a member of a large family of proteins, called
the bcl-2 family, which is involved in the regu-
lation of apoptosis.  Among its members, bax
has a unique effect and plays an important role.
It is able to heterodimerize with bcl-2 and alter
the latter’s antiapoptotic action (Garcia et al.,
1992).  bcl-2 blocks the preapoptotic actions of
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other members of the bcl-2 family such as bax
and bad (Dubal et al., 1999).  bcl-2 and other
members of the bcl-2 gene family have been
identified, in addition to being regulators of cell
death, as estrogen-responsive genes (Teixeira et
al., 1995; Kandouz et al., 1996).  E2 may directly
upregulate the survival factor through receptor-
mediated interactions with regions of the bcl-2
promoter or by indirect pathways (Teixeira et
al., 1995).  The antiapoptotic activity of bcl-2
correlates with its intracellular ratio to another
protein called Bax.  High levels of Bax have
been shown to favor apoptosis in cells subjected
to growth factor deprivation, whereas high
levels of Bcl-2 prolong cell survival under the
same conditions (Bafy et al., 1993).  Teixeria et
al. (1995) suggested that in the absence of E2,
the bax/bcl-2 ratio was increased and the cells
with estrogen receptors underwent apoptosis.
In the present study, it was suggested that
E2-replacement therapy might prevent apo-
ptosis mainly in the bladder mucosa through its
effect on the bcl-2 family in the bladder of old
female rats.  Although the reason why the activ-
ity was demonstrated chiefly in the mucosa is
not clear, one explanation might be the regula-
tion of the apoptotic reaction in the sensory re-
ceptors or nerve fibers in the bladder.  In fact,
recent studies have allowed conjecture that
the sensory nerve receptors against capsaicin
(Lecci et al., 1998; Shea et al., 1999), bradykinin
(Wotherspoon and Winter, 2000) and ATP
(Cockayne et al., 2000; Vlaskovska et al., 2001)
exist in the epithelial cells, and that the activa-
tion of the sensory nerves is related to urinary
incontinence, voiding and the sensations of
bladder fullness, discomfort and pain.
In this study, findings demonstrated that
estrogen administration to menopausal rats sup-
presses the expression of apoptosis-related
genes; bax mRNA was suppressed in the blad-
der of old female rats by estrogen administra-
tion, especially in the bladder mucosa, while the
addition of estrogen prevented a decrease in
contractile response induced by the absence of
estrogen (Longhurst et al., 1992; Diep and
Conatantinou, 1999).  Sensory nerve receptors
exist in the mucosa, and it might follow that
suppression of bax mRNA in the mucosa would
influence voiding behavior.
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